. Author manuscript; available in PMC: 2020 May 26.

Published in final edited form as: J Thorac Oncol. 2016 Sep 30;12(1):145–151. doi: 10.1016/j.jtho.2016.09.131

Table 4.

Response Based on Investigator Assessment

Objective Response/Response Duration	n (%)
Objective Response/Response Duration	Dose Level 1 (n = 7)	Dose Level −1 (n = 18)	All Patients (N = 25)

Partial response	1 (14)	1 (6)	2(8)
Stable disease	2 (29)	6 (33)	8(32)
Objective progression	4(57)	6 (33)	10 (40)
Early death	0	2(11)	2(8)
Indeterminate^a	0	3 (17)	3 (12)
Objective response rate, % (95% exact CI)	14 (<1–58)	6 (<1 −27)	8 (1–26)
Duration of stable disease^b
0 to <3 months	1 (50)	0	1 (13)
3 to <6 months	0	6 (100)	6(75)
6 to <9 months	0	0	0
9 to <12 months	0	0	0
>12 months	1 (50)	0	1 (13)

Note: Dose level of 1: crizotinib, 150 mg twice daily, plus erlotinib, 100 mg daily. Dose level of 1: crizotinib, 200 mg twice daily, plus erlotinib, 100 mg daily.

Withdrawn from study before first scan during treatment.

In patients with stable disease.

CI, confidence interval.